Abstract: The present invention relates to a method for estimating the effectiveness of treatment with an anti-CD20 agent in a patient with rheumatoid arthritis and who has had an inadequate response to at least one prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said agent is a treatment that will engender a beneficial response for said patient. The present invention also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data, the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of said treatment in said patient.
Abstract: The present invention relates to a method for estimating the effectiveness of treatment with an anti-TNF? agent in a patient with rheumatoid arthritis and who has had an inadequate response to at least one prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said agent is a treatment that will engender a beneficial response for said patient. The present invention also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data, the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of the treatment in said patient.
Type:
Application
Filed:
December 18, 2019
Publication date:
February 24, 2022
Applicant:
SINNOVIAL
Inventors:
Philippe GAUDIN, Athan BAILLET, Anaïs COURTIER, Minh-Vu-Chuong NGUYEN, Lisa GUIGUE, Jacques-Eric GOTTENBERG
Abstract: The disclosure relates to a method for estimating the effectiveness of treatment with a T-lymphocyte cell co-stimulation modulator agent in a patient with rheumatoid arthritis and who has had an inadequate response to prior biotherapy, consisting in analysing a biological sample of said patient for the expression of a set of biomarkers, the results of which make it possible to determine whether said modulator agent is a treatment that will engender a beneficial response for said patient. The disclosure also relates to a system for estimating the effectiveness of said treatment in said patient comprising means for measuring or receiving data concerning the expression level of said biomarkers and means for processing these data configured to estimate said effectiveness of said treatment in said patient.
Type:
Application
Filed:
October 18, 2018
Publication date:
July 30, 2020
Applicant:
SINNOVIAL
Inventors:
Anaïs COURTIER, Minh Vu Chuong NGUYEN, Athan BAILLET, Philippe GAUDIN, Jacques-Eric GOTTENBERG